D1.404 - Live Renal Transplantation Outcome in Egyptian Cohort: A Single Center Study

The treatment of choice for patients with end-stage renal disease (ESRD) is renal transplantation. Survival rates have improved because of effective immunosuppression. The immunosuppressive drugs adversely impact on patients risks.

A retrospective cohort study was conducted using 2020-2021 data of renal allograft adult recipients at National Institute of Urology and Nephrology with a minimum of 3-month follow-up.

Demographics showed mean age of 27.49±9.59 years and male predominance 73.2% with living 100% related-donors 95.1%. ESRD was identified as idiopathic 46%, Vesico-ureteric reflux 12%, and polycystic kidney disease 4.9% with preemptive dialysis 9.8%. Immunological data revealed blood group A 39%, HLA Mismatch 3/6 63.4%, PRA zero 87.8% & 97.6% (class-l and ll, respectively), DSA negative 97.6%, final cross match negative 100%, HCV-IgG positive 9.8%, HBV-sAg positive 2.4%, CMV-IgG positive 100%, with no history of previous transplant. Desensitization protocol rituximab and plasmapheresis 4.9%. Immunosuppressive Induction protocol ATG 26.8% and Basiliximab 2.4%. Post-transplant complications were delayed graft function 17.1% with post-transplant dialysis 7.3%, and Death 12.1%. There was no statistical significance between low and intermediate risk groups as regard the outcomes.

Immunosuppression in renal transplant recipients comprising ATG induction is effective in limiting acute rejection episodes but had no effect in limiting long-term post-transplant sequelae; patient survival or graft survival.